David Kerstein - 18 Feb 2022 Form 4 Insider Report for Theseus Pharmaceuticals, Inc.

Role
Chief Medical Officer
Signature
/s/ Bradford Dahms - Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
18 Feb 2022
Net transactions value
$0
Form type
4
Filing time
23 Feb 2022, 19:00:48 UTC
Previous filing
06 Oct 2021
Next filing
21 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction THRX Stock Option (right to buy) Award $0 +150,000 $0.000000 150,000 18 Feb 2022 Common Stock 150,000 $11.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the options vesting on February 18, 2023 and 1/48th of the options vesting monthly thereafter, subject to the Reporting Person's continuous service with the issuer.